| Dr Warren Michael Fraser, MD | |
|
4550 North Blvd, Suite 115, Baton Rouge, LA 70806-4013 | |
| (225) 341-5901 | |
| (225) 341-5903 |
| Full Name | Dr Warren Michael Fraser |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 53 Years |
| Location | 4550 North Blvd, Baton Rouge, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417146267 | NPI | - | NPPES |
| 1140252 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 011684 (Louisiana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hiv-aids Alliance For Region Two | 4880981158 | 15 |
News Archive
Otsuka Pharmaceutical Co., Ltd. announced that the European Commission has granted marketing authorisation for JINARC® (tolvaptan) for the treatment of ADPKD in adults who have chronic kidney disease (CKD) stage one to three at initiation of treatment with evidence of rapidly progressing disease
While many climate experts and environmentalists explore the negative effects of global warming, a new study reveals a positive outcome of the warming of the planet: the potential elimination of the plague. Global warming affects temperatures and precipitation regimes that play a pivotal role in the lives of rodents and fleas; rodents and fleas are responsible for maintenance and spread of plague to human populations. Plague can be fatal if the symptoms are not recognized and treated within 24 hours.
Exercise may play a key role in helping children cope with stressful situations, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).
New anti-arrhythmic agent, dronedarone, is highly effective in the prevention of atrial fibrillation or atrial flutter recurrence, serious disorders of cardiac rhythm, and is well-tolerated by patients.
Juventas Therapeutics, a privately held, clinical-stage regenerative medicine company announced it has started enrolling patients in a Phase I clinical trial for JVS-100 to evaluate safety and efficacy in the treatment of patients with Class III heart failure. JVS-100 encodes Stromal Cell-derived Factor-1 (SDF-1) and has been shown in pre-clinical studies to significantly increase cardiac function by promoting cell survival and increasing new blood vessel formation in the damaged organ.
› Verified 4 days ago
| Entity Name | Hiv-aids Alliance For Region Two |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437527900 PECOS PAC ID: 4880981158 Enrollment ID: O20181101000702 |
News Archive
Otsuka Pharmaceutical Co., Ltd. announced that the European Commission has granted marketing authorisation for JINARC® (tolvaptan) for the treatment of ADPKD in adults who have chronic kidney disease (CKD) stage one to three at initiation of treatment with evidence of rapidly progressing disease
While many climate experts and environmentalists explore the negative effects of global warming, a new study reveals a positive outcome of the warming of the planet: the potential elimination of the plague. Global warming affects temperatures and precipitation regimes that play a pivotal role in the lives of rodents and fleas; rodents and fleas are responsible for maintenance and spread of plague to human populations. Plague can be fatal if the symptoms are not recognized and treated within 24 hours.
Exercise may play a key role in helping children cope with stressful situations, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).
New anti-arrhythmic agent, dronedarone, is highly effective in the prevention of atrial fibrillation or atrial flutter recurrence, serious disorders of cardiac rhythm, and is well-tolerated by patients.
Juventas Therapeutics, a privately held, clinical-stage regenerative medicine company announced it has started enrolling patients in a Phase I clinical trial for JVS-100 to evaluate safety and efficacy in the treatment of patients with Class III heart failure. JVS-100 encodes Stromal Cell-derived Factor-1 (SDF-1) and has been shown in pre-clinical studies to significantly increase cardiac function by promoting cell survival and increasing new blood vessel formation in the damaged organ.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Warren Michael Fraser, MD 4550 North Blvd, Suite 115, Baton Rouge, LA 70806-4013 Ph: (225) 341-5901 | Dr Warren Michael Fraser, MD 4550 North Blvd, Suite 115, Baton Rouge, LA 70806-4013 Ph: (225) 341-5901 |
News Archive
Otsuka Pharmaceutical Co., Ltd. announced that the European Commission has granted marketing authorisation for JINARC® (tolvaptan) for the treatment of ADPKD in adults who have chronic kidney disease (CKD) stage one to three at initiation of treatment with evidence of rapidly progressing disease
While many climate experts and environmentalists explore the negative effects of global warming, a new study reveals a positive outcome of the warming of the planet: the potential elimination of the plague. Global warming affects temperatures and precipitation regimes that play a pivotal role in the lives of rodents and fleas; rodents and fleas are responsible for maintenance and spread of plague to human populations. Plague can be fatal if the symptoms are not recognized and treated within 24 hours.
Exercise may play a key role in helping children cope with stressful situations, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).
New anti-arrhythmic agent, dronedarone, is highly effective in the prevention of atrial fibrillation or atrial flutter recurrence, serious disorders of cardiac rhythm, and is well-tolerated by patients.
Juventas Therapeutics, a privately held, clinical-stage regenerative medicine company announced it has started enrolling patients in a Phase I clinical trial for JVS-100 to evaluate safety and efficacy in the treatment of patients with Class III heart failure. JVS-100 encodes Stromal Cell-derived Factor-1 (SDF-1) and has been shown in pre-clinical studies to significantly increase cardiac function by promoting cell survival and increasing new blood vessel formation in the damaged organ.
› Verified 4 days ago
Dr. Jennifer L Rippon, D.O. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 7777 Hennessy Blvd Ste 409, Baton Rouge, LA 70808 Phone: 225-765-5864 Fax: 225-765-2013 | |
Gregory Fusilier, M.D. Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 9103 Jefferson Hwy, Baton Rouge, LA 70809 Phone: 225-927-1190 Fax: 225-927-0988 | |
Dr. Yolanda Maria O'rourke, Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 7968 Essen Park, Baton Rouge, LA 70809 Phone: 225-761-6700 Fax: 225-761-6760 | |
Patricia D. Whatley, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 7373 Perkins Rd, Attn: Dee / Administration, Baton Rouge, LA 70808 Phone: 225-769-4044 | |
Frederick Cerise, Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 3810 W Lakeshore Dr, Baton Rouge, LA 70808 Phone: 225-578-8886 | |
Dr. Jon Richard Jackson, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 5000 Hennessy Blvd, Baton Rouge, LA 70808 Phone: 225-765-4050 Fax: 225-765-4046 | |
Richard Frank Burroughs, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: Earl K. Long Hospital, Lsu Unit, 5825 Airline Highway, Baton Rouge, LA 70805 Phone: 225-358-3938 |